News & Media

Amorsa Therapeutics Announces Strategic Collaboration Facilitated by Johnson & Johnson Innovation to Develop New Therapy for Treatment-­‐Resistant Depression

Southborough, MA, January 5, 2017 – Amorsa Therapeutics, Inc., a neuropharmaceutical company pioneering the development of breakthrough treatments for nervous system disorders has announced a research, option and license agreement with Janssen Pharmaceuticals, Inc. to develop and commercialize a novel small molecule drug candidate for treatment-resistant depression based on Amorsa’s proprietary ketamine analog technology. Amorsa’s product candidates are designed to show efficacy as rapidly acting antidepressants with an extended duration of action, possess an attractive side-effect profile, and enable oral dose administration. Under the terms of the agreement, facilitated by Johnson & Johnson Innovation, Amorsa will receive an upfront payment, More

Amorsa Therapeutics Appoints Anita Gupta, D.O., Pharm.D., to its Board of Directors

Littleton, MA., Nov. 1, 2016 – Amorsa Therapeutics, a neuropharmaceutical company pioneering the development and commercialization of breakthrough treatments for nervous system disorders, is pleased to announce today that Anita Gupta, D.O., Pharm.D., has been appointed to Amorsa’s Board of Directors. “We are extremely proud to welcome Anita to our Board,” said Joe Blanchard, President and Chief Executive Officer of Amorsa. “Anita’s contributions to the field have been instrumental to the continued advancement of improved treatment options for neurological diseases. Her extensive drug development experience, along with her broad regulatory, clinical, and strategic insight will be invaluable to Amorsa.” Dr. Gupta More

Amorsa Therapeutics Selected to Present at Cavendish Global Health Impact Forum

Forum uniquely brings together leading family offices, their foundations and sovereign wealth fund representatives seeking impact investment, grant-giving, and philanthropy opportunities within health and life sciences Littleton, MA, Feb. 1, 2016 — Amorsa Therapeutics, a preclinical stage, neuropharmaceutical company, announced today it has been selected to present at the Cavendish Global Health Impact Forum taking place February 15th to February 18th at the Breakers in Palm Beach, Florida. The purpose of the Forum is to help family offices and foundations develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences. To accomplish More